Mayo Foundation for Medical Education & Research v. United States

Eko Health Launches CORE 500™ Digital Stethoscope with Heart Disease Detection AI, 3-Lead ECG, and Advanced Audio Capabilities

Retrieved on: 
Tuesday, June 27, 2023
Auscultation, Heart, Bradycardia, Mayo Clinic, Emergency medicine, Ventricular fibrillation, Jawaharlal Institute of Postgraduate Medical Education and Research, Cardiovascular disease, Health, Mayo Foundation for Medical Education & Research v. United States, Stethoscope, ECG, Arrhythmia, Lung, Tachycardia, Patient, Machine learning, Algorithm, Artificial intelligence, Eko, CORE, Heart rate, Research, FDA, Medical education, Medical device

EMERYVILLE, Calif., June 27, 2023 /PRNewswire/ -- Eko Health, a leading innovator in digital health technology for heart and lung disease detection, today announced the launch of its next-generation digital stethoscope, CORE 500™. The CORE 500™ Digital Stethoscope represents over 10 years of pioneering the industry of digital auscultation (listening to heart, lung, and body sounds). Engineered to enhance diagnostic accuracy and early disease detection, the CORE 500™ combines artificial intelligence (AI) software, high-fidelity audio experience, full-color display, and 3-lead electrocardiogram (ECG) to deliver an essential patient assessment tool for healthcare professionals (HCPs).  

Key Points: 
  • EMERYVILLE, Calif., June 27, 2023 /PRNewswire/ -- Eko Health , a leading innovator in digital health technology for heart and lung disease detection, today announced the launch of its next-generation digital stethoscope, CORE 500™ .
  • The CORE 500™ Digital Stethoscope represents over 10 years of pioneering the industry of digital auscultation (listening to heart, lung, and body sounds).
  • "The CORE 500™ represents a major leap forward in digital stethoscope technology.
  • To learn more about the availability of CORE 500™ for your health system, please contact Eko Health at ekohealth.com/enterprise .

InSitu Biologics Announces License Agreement With Mayo Clinic For Co-Development of Anti-Cancer Therapeutics

Retrieved on: 
Thursday, December 22, 2022
Technology, Biotechnology, Nanotechnology, Health, Other Health, Pharmaceutical, Philanthropy, Oncology, Other Science, Research, General Health, Hospitals, Foundation, Science, Education, Cancer, Partnership, Infection, Medical education, Pain, Research, Geography, Insitu, Pain management, Patient, Innovation, Mayo, Physician, Health, Therapy, Jawaharlal Institute of Postgraduate Medical Education and Research, Mayo Foundation for Medical Education & Research v. United States, Sale, Mayo Clinic, Pharmaceutical industry

InSitu Biologics has developed an industry-leading platform technology for loading large doses of a variety of medications into a localized delivery matrix.

Key Points: 
  • InSitu Biologics has developed an industry-leading platform technology for loading large doses of a variety of medications into a localized delivery matrix.
  • The collaboration with Mayo is both a research and commercial endeavor, and will accelerate InSitu Biologics’ work in adapting this technology for anti-cancer therapeutics.
  • “Combining Mayo’s world-class expertise with InSitu Biologics’ unique technology should yield novel and effective treatment solutions for cancer patients.
  • Mayo now holds a financial interest in InSitu Biologics and its platform technology.

Canon Medical and Resoundant, Inc. Partnership to Provide Magnetic Resonance Elastography on Canon MRI Scanners

Retrieved on: 
Tuesday, November 30, 2021
Radiology, Health, Medical Devices, Patient, Mayo Clinic, American College of Radiology, Heart, Mayo Foundation for Medical Education & Research v. United States, CEO, Safety, Technology, Noise, AI, General manager, AICE, Health care, ReSound, Google Images, NAFLD, Fatty liver disease, MD, Diagnosis, Canon Medical Systems Corporation, Health, Radiology, Appropriate use criteria, Solution, MRE, Magnetic resonance elastography, Trust, Cirrhosis, Research, Non-alcoholic fatty liver disease, Medical education, Ministry of Education (Malaysia), MRI, American College, NASH, CT, Medical research, Nuclear medicine, Life, Blanche, Quality of life, Medical imaging, MRE, Resoundant, Canon Medical Systems, MRE, RESOUNDANT, CANON MEDICAL SYSTEMS

Canon Medical Systems Corporation and Resoundant, Inc. (Rochester, MN, USA) have signed a licensing agreement for the purpose of incorporating the advanced Magnetic Resonance Elastography (MRE), developed by Resoundant on the Canon MRI platforms.

Key Points: 
  • Canon Medical Systems Corporation and Resoundant, Inc. (Rochester, MN, USA) have signed a licensing agreement for the purpose of incorporating the advanced Magnetic Resonance Elastography (MRE), developed by Resoundant on the Canon MRI platforms.
  • Canon Medical and Resoundant have been working closely together to implement a seamless integration of the latest MRE technology on Canons newest line of MRI scanners.
  • MR Elastography was invented at Mayo Clinic and is the only MRI technology that has been validated for staging liver fibrosis.
  • Resoundant, Inc. is a medical technology company dedicated to improving patient care and diagnosis accuracy by making Magnetic Resonance Elastography (MRE) available around the world.

Immunome Reports Second Quarter 2021 Financial Results

Retrieved on: 
Thursday, August 19, 2021
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Oncology, Industry, Drug discovery, COVID-19 Advisory Board, Private Securities Litigation Reform Act, Department of Defense Architecture Framework, Program, Therapy, Severe acute respiratory syndrome coronavirus 2, U.S. Securities and Exchange Commission, Antibody, Infection, Immune system, Mayo Foundation for Medical Education & Research v. United States, SEC, Association, United States Department of Defense, CDC, Board of directors, Research, Radiation, Nasdaq, Disease, R, IMM, Private placement, Forward-looking statement, CFO, Alpha, Clinical professor, G&A, Biotechnology, Clinical trial, U.S. Department of Defense Strategy for Operating in Cyberspace, Contract, Board, Coronavirus Scientific Advisory Board (Turkey), Mayo Clinic, Mayo, IND, Goal, Patient, CEO, Gamma, Beta, COVID-19, Department, Fine chemical, Pharmaceutical industry, Vaccine, Management, Tutoring

Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.

Key Points: 
  • Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.
  • We believe we are well-positioned for an IND filing for this program in the third quarter, said Purnanand Sarma, Ph.D., President and CEO of Immunome.
  • In July 2021, Immunome announced that its three-antibody cocktail (IMM-BCP-01) has demonstrated potent neutralizing activity against the SARS-CoV-2 Delta variant in pre-clinical pseudovirus testing.
  • In April 2021, Immunome announced that it had appointed Corleen Roche as its Chief Financial Officer.